Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
2023 · Nature Medicine · 348 citations
https://doi.org/10.1038/s41591-022-02103-8
S
Siqing Fu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
923
Papers
15.0K
Citations
64
h-index
233
i10-index
Siqing Fu is an academic researcher from The University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer Genomics and Diagnostics & Lung Cancer Treatments and Mutations & Colorectal Cancer Treatments and Studies. The author has an h-index of 64, co-authored 785 publications.
ORCID: 0000-0002-1933-0419Papers by this author
worksPhase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
2019 · Journal for ImmunoTherapy of Cancer · 152 citations
https://doi.org/10.1186/s40425-019-0722-x
Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma
2013 · British Journal of Cancer · 132 citations
https://doi.org/10.1038/bjc.2013.46
Phase 2 study of pembrolizumab in patients with advanced rare cancers
2020 · Journal for ImmunoTherapy of Cancer · 127 citations
https://doi.org/10.1136/jitc-2019-000347
Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials
2018 · British Journal of Cancer · 39 citations
https://doi.org/10.1038/bjc.2017.480
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers
2021 · ESMO Open · 38 citations
https://doi.org/10.1016/j.esmoop.2021.100230
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat